Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS...

Full description

Bibliographic Details
Main Authors: Claudia Minosse, Cesare E. M. Gruber, Martina Rueca, Chiara Taibi, Mauro Zaccarelli, Elisabetta Grilli, Marzia Montalbano, Maria R. Capobianchi, Andrea Antinori, Gianpiero D’Offizi, Fiona McPhee, Anna Rosa Garbuglia
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Viruses
Subjects:
hepatitis C virus
HCV
HCV reinfection
HCV late relapse
next-generation sequencing
NGS
Online Access:https://www.mdpi.com/1999-4915/13/6/1151

Internet

https://www.mdpi.com/1999-4915/13/6/1151

Similar Items